Cardinal Health (CAH) has been identified as a #2 (Buy) on the Zacks Rank with an A VGM Score. The healthcare services provider is forecasted to achieve 11.5% year-over-year earnings growth for the current fiscal year, with three analysts revising earnings estimates higher in the last 60 days. The company boasts a strong Growth Style Score of A and an average earnings surprise of +14.7%.

A comprehensive market report on China's patient examination devices market covering thermometers and stethoscopes through 2033. The report provides revenue, volume, and pricing data for medical device manufacturers, investors, and healthcare stakeholders, with 2025 company share analysis and competitive intelligence on key market players.

Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment.

Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation.

Freehand, an AI workforce platform for procurement and accounts payable operations, showcased its solutions at LogiPharma USA 2026. CEO Nitin Jayakrishnan participated in a keynote panel discussing supply chain resilience in the pharmaceutical industry. The company, which serves major healthcare enterprises including Johnson & Johnson and Pfizer, recently raised $75 million in funding to scale its AI Teams that automate complex procurement and spend management processes.

Cardinal Health closed at $233.12, up 2.11% and outpacing the S&P 500's 0.66% gain. However, the stock has fallen 7.64% over the past month, lagging the Medical sector. The company is expected to report earnings on November 5, 2026, with predicted EPS of $2.92 (up 14.51% YoY) and revenue of $66.96 billion (up 4.6% YoY). Cardinal Health holds a Zacks Rank of #3 (Hold) with a Forward P/E of 18.19, trading at a premium to its industry average.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets.

Cardinal Health (CAH) closed down 1.64% and is expected to report EPS of $2.92 (up 14.51% YoY) with revenue of $66.96 billion (up 4.6% YoY). The stock holds a Zacks Rank #3 (Hold) with a Forward P/E of 17.99, trading at a premium to its industry average. The Medical-Dental Supplies industry ranks in the top 44% of all industries.

While Cardinal Health (CAH) has a strong average brokerage recommendation of 1.39 (Strong Buy equivalent) from 18 firms, the article cautions that broker recommendations are often overly optimistic due to vested interests. The Zacks Rank system rates CAH as a #3 (Hold), citing unchanged earnings estimates of $12.55 for the current year, suggesting the stock may perform in line with the broader market in the near term.

AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

The article provides an analysis of the Nuveen ESG Mid-Cap Value ETF (NUMV), a smart beta ETF launched in 2016 with $442.53 million in assets. NUMV tracks the TIAA ESG USA Mid-Cap Value Index with a 0.31% expense ratio and has returned 11.92% year-to-date and 14.53% over the past year. The fund holds 89 companies with heaviest exposure to Financials (19.6%), Industrials, and Information Technology sectors. Alternative ESG ETFs like ESGV and ESGU are also mentioned as comparable options.